ACM
ADAR1 Capital Management Portfolio holdings
AUM
$616M
1-Year Return
26.77%
This Quarter Return
-4.37%
1 Year Return
+26.77%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$520M
AUM Growth
+$34.5M
(+7.1%)
Cap. Flow
+$41M
Cap. Flow
% of AUM
7.89%
Top 10 Holdings %
Top 10 Hldgs %
45.71%
Holding
253
New
46
Increased
68
Reduced
40
Closed
49
Top Buys
| 1 |
Keros Therapeutics
KROS
|
$14.9M |
| 2 |
SWTX
SpringWorks Therapeutics
SWTX
|
$9.17M |
| 3 |
iShares 1-3 Year Treasury Bond ETF
SHY
|
$8.55M |
| 4 |
ITCI
Intra-Cellular Therapies Inc.
ITCI
|
$6.34M |
| 5 |
RAPT Therapeutics
RAPT
|
$5.85M |
Top Sells
| 1 |
BridgeBio Pharma
BBIO
|
$11.7M |
| 2 |
Ascendis Pharma
ASND
|
$10.9M |
| 3 |
Mineralys Therapeutics
MLYS
|
$9.18M |
| 4 |
EDR
Endeavor Group Holdings, Inc.
EDR
|
$6.59M |
| 5 |
Sanofi
SNY
|
$4.8M |
Sector Composition
| 1 | Healthcare | 80.96% |
| 2 | Financials | 3.59% |
| 3 | Consumer Discretionary | 0.06% |
| 4 | Utilities | 0.02% |
| 5 | Communication Services | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
126
Voyager Therapeutics
VYGR
$235M
| $255K | 0.05% |
75,545
-51,247
| -40% | -$173K |
|
127
Nurix Therapeutics
NRIX
$758M
| $252K | 0.05% |
21,200
+10,200
| +93% | +$121K |
|
128
Gossamer Bio
GOSS
$668M
| $250K | 0.05% |
227,228
-68,385
| -23% | -$75.2K |
|
129
TherapeuticsMD
TXMD
$12.5M
| $250K | 0.05% |
270,160
| – | – |
|
130
Spyre Therapeutics
SYRE
$1.03B
| $243K | 0.05% |
+15,033
| New | +$243K |
|
131
Day One Biopharmaceuticals
DAWN
$773M
| $222K | 0.04% |
28,023
-25,000
| -47% | -$198K |
|
|
132
Ascendis Pharma
ASND
$12.5B
| $219K | 0.04% |
1,402
-70,000
| -98% | -$10.9M |
|
133
PolyPid
PYPD
$54.8M
| $217K | 0.04% |
80,080
| – | – |
|
134
Exact Sciences
EXAS
$10.2B
| $216K | 0.04% |
5,000
| – | – |
|
135
Context Therapeutics
CNTX
$73.6M
| $215K | 0.04% |
351,094
| – | – |
|
136
MoonLake Immunotherapeutics
MLTX
$3.77B
| $212K | 0.04% |
5,424
-12,000
| -69% | -$469K |
|
137
Stoke Therapeutics
STOK
$1.13B
| $200K | 0.04% |
+30,085
| New | +$200K |
|
|
CLBR
138
DELISTED
Colombier Acquisition Corp II
CLBR
| $197K | 0.04% |
+18,513
| New | +$197K |
|
139
Quince Therapeutics
QNCX
$86.5M
| $190K | 0.04% |
142,958
| – | – |
|
140
Denali Therapeutics
DNLI
$2.26B
| $189K | 0.04% |
13,873
-30,953
| -69% | -$421K |
|
141
Wave Life Sciences
WVE
$1.32B
| $187K | 0.03% |
23,100
+1,400
| +6% | +$11.3K |
|
142
BiomX
PHGE
$13.7M
| $166K | 0.03% |
+299,598
| New | +$166K |
|
143
Kura Oncology
KURA
$713M
| $165K | 0.03% |
+25,000
| New | +$165K |
|
144
Acumen Pharmaceuticals
ABOS
$87.2M
| $161K | 0.03% |
146,183
+51,889
| +55% | +$57.1K |
|
145
Organon & Co
OGN
$2.7B
| $149K | 0.03% |
10,000
-30,200
| -75% | -$450K |
|
|
CLYM
146
Climb Bio, Inc. Common Stock
CLYM
$162M
| $146K | 0.03% |
119,320
+71,195
| +148% | +$86.9K |
|
147
Anavex Life Sciences
AVXL
$807M
| $139K | 0.03% |
16,221
| – | – |
|
148
Immunome
IMNM
$916M
| $135K | 0.03% |
+20,000
| New | +$135K |
|
149
Solid Biosciences
SLDB
$428M
| $128K | 0.02% |
34,479
-114,424
| -77% | -$423K |
|
|
SPRB
150
DELISTED
Spruce Biosciences, Inc. Common Stock
SPRB
| $117K | 0.02% |
403,716
| – | – |
|